NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
7 trialsNCT01950390 2025-12-11
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02304458 2023-10-17
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT03396952 2022-10-13
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
University of California, San Francisco
Phase 2 Completed
NCT02158520 2020-01-21
Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery
Academic and Community Cancer Research United
Phase 2 Completed
NCT00871481 2017-04-19
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00050102 2011-01-28
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma
Bristol-Myers Squibb
Phase 2 Completed